Attovia holder plans 105K-share resale via Goldman
Attovia Therapeutics, Inc. (ATTO) is the issuer in a Notice of Proposed Sale of Securities on Form 144 filed in connection with planned sales of its common stock by Goldman Sachs Group Inc., identified as a former 10% owner.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Attovia Therapeutics, Inc. (ATTO) is the issuer in a Notice of Proposed Sale of Securities on Form 144 filed in connection with planned sales of its common stock by Goldman Sachs Group Inc., identified as a former 10% owner. The notice covers up to 105,807 shares of Attovia common stock. The shares to be sold were acquired through securities borrowing by Goldman Sachs & Co. LLC, which is acting as a market maker in the ordinary course of business, and trades may occur on CBOE, IEX, MEMX and Nasdaq. The Form 144 is a resale notice for the selling party; Attovia does not sell shares or receive proceeds in this transaction.
Key Figures
Key Terms
Rule 144 regulatory
securities borrowing financial
market maker financial
Former 10% Owner regulatory
Form 144 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 filing mean for Attovia Therapeutics, Inc. (ATTO)?
Does Attovia Therapeutics (ATTO) receive any proceeds from this Form 144 sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.